Breaking News, Collaborations & Alliances

CDMO Matica Bio Partners with Treovir for Pediatric Cancer Therapy

Will provide GMP manufacturing for clinical supplies.

Author Image

By: Charlie Sternberg

Associate Editor

Matica Biotechnology, a contract development and manufacturing organization (CDMO) specializing in viral vector development and manufacturing, has partnered with Treovir, a biotechnology company developing oncolytic immunotherapies, to advance innovative therapies for pediatric patients with brain and other neurological cancers. Matica Bio will provide GMP manufacturing for clinical supplies.   Treovir will partner with Matica Bio on its G207 HSV-based oncolytic therapy for treating glioblasto...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters